Shelton Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.7M Buy
49,244
+1,789
+4% +$397K 0.23% 97
2025
Q4
$10.8M Sell
47,455
-3,031
-6% -$690K 0.21% 103
2025
Q3
$11.7M Buy
50,486
+11,210
+29% +$2.28M 0.25% 98
2025
Q2
$7.29M Sell
39,276
-11,804
-23% -$2.19M 0.17% 126
2025
Q1
$10.7M Sell
51,080
-35,116
-41% -$6.83M 0.25% 103
2024
Q4
$15.3M Sell
86,196
-6,784
-7% -$1.25M 0.38% 51
2024
Q3
$18.4M Sell
92,980
-32,661
-26% -$6.1M 0.47% 37
2024
Q2
$21.5M Buy
125,641
+7,900
+7% +$1.31M 0.59% 32
2024
Q1
$21.4M Buy
117,741
+22,117
+23% +$3.81M 0.61% 30
2023
Q4
$14.8M Buy
95,624
+29,053
+44% +$4.24M 0.47% 46
2023
Q3
$9.92M Sell
66,571
-4,200
-6% -$617K 0.36% 62
2023
Q2
$9.53M Buy
70,771
+3,428
+5% +$503K 0.34% 58
2023
Q1
$10.7M Buy
67,343
+48,343
+254% +$7.39M 0.45% 48
2022
Q4
$3.07M Sell
19,000
-42,413
-69% -$6.5M 0.32% 106
2022
Q3
$8.24M Sell
61,413
-2
-0% -$287 0.39% 66
2022
Q2
$9.41M Sell
61,415
-9,928
-14% -$1.52M 0.42% 60
2022
Q1
$11.6M Buy
71,343
+4,904
+7% +$712K 0.43% 48
2021
Q4
$9M Buy
66,439
+3,615
+6% +$427K 0.32% 70
2021
Q3
$6.78M Sell
62,824
-1,156
-2% -$132K 0.26% 89
2021
Q2
$7.21M Buy
63,980
+9,313
+17% +$1.05M 0.27% 84
2021
Q1
$5.92M Buy
54,667
+1,188
+2% +$127K 0.21% 108
2020
Q4
$5.73M Sell
53,479
-68,662
-56% -$6.6M 0.26% 79
2020
Q3
$10.7M Buy
122,141
+66,471
+119% +$6.26M 0.44% 44
2020
Q2
$5.47M Buy
55,670
+1,686
+3% +$148K 0.3% 64
2020
Q1
$4.11M Buy
53,984
+1,000
+2% +$85.2K 0.3% 69
2019
Q4
$4.69M Sell
52,984
-50,182
-49% -$4.17M 0.26% 79
2019
Q3
$7.81M Sell
103,166
-7,800
-7% -$535K 0.46% 51
2019
Q2
$8.07M Buy
110,966
+98,606
+798% +$7.75M 0.46% 49
2019
Q1
$153K Sell
12,360
-143,823
-92% -$11.8M 0.6% 27
2018
Q4
$14.4M Buy
156,183
+300
+0.2% +$26.4K 0.98% 17
2018
Q3
$14.7M Buy
155,883
+12,300
+9% +$1.17M 0.84% 22
2018
Q2
$13.3M Buy
143,583
+18,400
+15% +$1.8M 0.83% 20
2018
Q1
$11.8M Sell
125,183
-4,416
-3% -$485K 0.78% 24
2017
Q4
$12.5M Buy
129,599
+1,800
+1% +$170K 0.8% 20
2017
Q3
$11.4M Buy
127,799
+47,700
+60% +$3.63M 0.77% 21
2017
Q2
$5.81M Sell
80,099
-10,800
-12% -$726K 0.41% 49
2017
Q1
$5.92M Sell
90,899
-15,032
-14% -$945K 0.41% 46
2016
Q4
$6.63M Sell
105,931
-4,250
-4% -$259K 0.51% 31
2016
Q3
$6.95M Sell
110,181
-50,831
-32% -$3.29M 0.58% 26
2016
Q2
$9.97M Buy
161,012
+9,307
+6% +$567K 0.88% 18
2016
Q1
$8.66M Sell
151,705
-25,543
-14% -$1.42M 0.78% 21
2015
Q4
$10.5M Buy
177,248
+15,159
+9% +$873K 1.02% 15
2015
Q3
$8.82M Buy
162,089
+2,419
+2% +$157K 0.97% 15
2015
Q2
$10.7M Sell
159,670
-42,276
-21% -$2.76M 1.11% 14
2015
Q1
$11.8M Buy
201,946
+186
+0.1% +$11.2K 1.28% 8
2014
Q4
$13.2M Buy
201,760
+3,400
+2% +$214K 1.54% 5
2014
Q3
$11.5M Buy
198,360
+15,500
+8% +$861K 1.54% 5
2014
Q2
$10.3M Sell
182,860
-1,728
-0.9% -$90.7K 1.44% 5
2014
Q1
$9.49M Buy
184,588
+13
+0% +$657 1.39% 4
2013
Q4
$9.75M Buy
184,575
+14
+0% +$688 1.47% 4
2013
Q3
$8.26M Buy
184,561
+16
+0% +$709 1.38% 6
2013
Q2
$7.63M Buy
+184,545
New +$8.07M 1.39% 6

Other funds holding ABBV

Shelton Capital Management's ABBV Position: Q1 2026 in Review

Shelton Capital Management increased its AbbVie (ABBV) stake by 3.8% in Q1 2026, buying an estimated $397K and bringing the position to 49,244 shares worth $10.7M. The position accounts for 0.23% of the portfolio, ranked #97.

Shelton Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.5M in Q2 2024. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Shelton Capital Management held 49,244 shares of AbbVie worth $10.7M as of Q1 2026.
  • Shelton Capital Management bought 1,789 AbbVie shares in Q1 2026, an estimated $397K.
  • AbbVie made up 0.23% of Shelton Capital Management's portfolio in Q1 2026, its #97 holding.
  • Shelton Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Shelton Capital Management's AbbVie position peaked at $21.5M in Q2 2024.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Shelton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.